CRISPR–Cas9 Screening Identifies KRAS-Induced COX2 as a Driver of Immunotherapy Resistance in Lung Cancer
2024 · Cancer Research · 25 citations
https://doi.org/10.1158/0008-5472.can-23-2627
M
Mona Tomaschko
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
53
Papers
167
Citations
4
h-index
4
i10-index
Mona Tomaschko is an academic researcher from The Francis Crick Institute. The author has contributed to research in topics: Synthesis and Biological Evaluation & Synthesis and biological activity & Cancer Immunotherapy and Biomarkers. The author has an h-index of 4, co-authored 46 publications.
ORCID: 0009-0003-1656-3326Papers by this author
worksCombining RAS(ON) G12C-selective inhibitor with SHP2 inhibition sensitises lung tumours to immune checkpoint blockade
2024 · Nature Communications · 16 citations
https://doi.org/10.1038/s41467-024-52324-3
Covalent inhibitors of the PI3Kα RAS binding domain impair tumor growth driven by RAS and HER2
2025 · Science · 3 citations
https://doi.org/10.1126/science.adv2684
Data from CRISPR–Cas9 Screening Identifies KRAS-Induced COX2 as a Driver of Immunotherapy Resistance in Lung Cancer
2024 · 0 citations
https://doi.org/10.1158/0008-5472.c.7348751
Figure 2 from CRISPR–Cas9 Screening Identifies KRAS-Induced COX2 as a Driver of Immunotherapy Resistance in Lung Cancer
2024 · 0 citations
https://doi.org/10.1158/0008-5472.26302484
Supplementary Figure 1 from CRISPR–Cas9 Screening Identifies KRAS-Induced COX2 as a Driver of Immunotherapy Resistance in Lung Cancer
2024 · 0 citations
https://doi.org/10.1158/0008-5472.26302466
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat